Jardiance vs Lantus: What to Do When One Fails

How Each Drug Actually Lowers Blood Sugar

Jardiance and Lantus do not compete for the same biochemical target. Jardiance forces the kidney to excrete roughly 60 to 90 grams of glucose per day through urine by blocking the sodium-glucose cotransporter 2 protein. Lantus provides exogenous insulin that suppresses hepatic glucose output overnight and allows peripheral glucose uptake. These are parallel pathways, which is why combining them is logical when either fails alone.

Empagliflozin: Glucose Lowering Through the Kidney

Empagliflozin's glucose-lowering effect is insulin-independent. That matters clinically because it works even when beta-cell function is severely impaired, though its effect weakens as estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m². The FDA label for empagliflozin notes that glycemic efficacy is reduced when eGFR is persistently between 30 and 44.

HbA1c reductions in placebo-controlled trials average 0.5 to 0.8 percentage points from a baseline near 8.0%. The drug also lowers systolic blood pressure by 3 to 5 mmHg and reduces body weight by 2 to 3 kg through caloric glycosuria.

Insulin Glargine: Replacing What the Pancreas Can No Longer Supply

Insulin glargine U-100 (Lantus) provides a peakless 24-hour basal insulin profile after subcutaneous injection. Starting doses are typically 10 units per day or 0.1 to 0.2 units/kg/day, titrated upward by 2 units every 3 days until fasting glucose reaches 80 to 130 mg/dL per the ADA Standards of Care. The ORIGIN trial (N=12,537) confirmed that titrated insulin glargine targeting fasting glucose below 95 mg/dL did not increase cardiovascular events compared with standard care over a median 6.2 years.

HbA1c reductions are larger than with empagliflozin, averaging 1.5 to 3.5 percentage points depending on baseline. The trade-off is weight gain of 1 to 4 kg and a non-trivial rate of symptomatic hypoglycemia.

The Evidence Base: EMPA-REG OUTCOME and ORIGIN

These two trials define the risk-benefit field for both drugs over the long term.

EMPA-REG OUTCOME: Cardiovascular and Kidney Outcomes

In EMPA-REG OUTCOME (N=7,020), patients with type 2 diabetes and established cardiovascular disease randomized to empagliflozin 10 mg or 25 mg had a 14% relative risk reduction in the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared with placebo (10.5% vs 12.1%, HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority and P=0.04 for superiority). Cardiovascular death alone was reduced by 38%. Hospitalization for heart failure dropped by 35%.

The kidney data from the same trial showed a 39% reduction in incident or worsening nephropathy. These outcomes emerged within months of randomization, well before meaningful HbA1c differences accumulated between arms, suggesting the benefit is partly independent of glucose control.

ORIGIN: Long-Term Safety of Basal Insulin

ORIGIN enrolled 12,537 people with dysglycemia, impaired fasting glucose, or early type 2 diabetes. After 6.2 years on titrated insulin glargine, the hazard ratio for major adverse cardiovascular events was 1.02 (95% CI 0.94 to 1.11), confirming cardiovascular neutrality. The ORIGIN investigators wrote: "Insulin glargine did not increase the risk of cardiovascular outcomes or cancer, and it decreased incident diabetes."

The key caveat: ORIGIN enrolled lower-risk patients than EMPA-REG OUTCOME. When a patient already has established heart disease or chronic kidney disease, the cardiovascular benefit of empagliflozin is a strong reason to prioritize it or keep it in the regimen even after adding insulin.

Defining Failure: When Is a Drug Actually Not Working?

"Failure" means inadequate glycemic response after 3 months at the maximum tolerated dose, not just any rise in blood sugar. Before labeling either drug a failure, confirm these four points.

Adherence and Titration Check

Lantus frequently appears to fail because it was never adequately titrated. A patient on 10 units for 12 months with an HbA1c of 9.0% has undertreated disease, not insulin failure. The ADA Standards of Medical Care in Diabetes recommends a basal insulin titration algorithm targeting fasting glucose 80 to 130 mg/dL, with dose increases every 2 to 3 days.

Jardiance, by contrast, has a ceiling effect built into its mechanism. Once the SGLT2 transporter is fully occupied at 10 mg, the 25 mg dose adds modest incremental glycemic benefit (roughly 0.1 to 0.15% additional HbA1c reduction). If a patient on 25 mg empagliflozin and metformin still has HbA1c above 8.5%, the drug is not failing in isolation; beta-cell reserve is simply too depleted for the drug's mechanism to compensate.

eGFR and Kidney Function

Empagliflozin loses most of its glucose-lowering effect when eGFR drops below 30. A patient whose eGFR fell from 55 to 28 over 18 months may look like a Jardiance failure when the drug's mechanism is simply restricted by physiology. Check eGFR before concluding the drug failed.

Differentiating Primary From Secondary Failure

Primary failure: HbA1c never reached target after 3 months at optimal dose. Secondary failure: HbA1c was controlled for at least 6 months and then rose. Secondary failure of Lantus almost always signals progressive beta-cell loss requiring prandial insulin or a GLP-1 receptor agonist added to the regimen. Secondary failure of Jardiance at a maintained eGFR often signals that postprandial glucose is now the dominant problem, which basal insulin addresses directly.

When Jardiance Fails: Should You Switch to Lantus or Add It?

Switching entirely from empagliflozin to insulin glargine is rarely the right move for a patient with established cardiovascular disease or an eGFR between 30 and 60. The cardiovascular and kidney benefits of empagliflozin documented in EMPA-REG OUTCOME persist regardless of glucose-lowering adequacy. Stopping the drug to swap medications forfeits organ-protective effects that go beyond blood sugar.

The Combination Strategy

Adding basal insulin to an existing empagliflozin regimen is guideline-supported. The ADA 2024 Standards state: "If additional glycemic-lowering is needed, agents with complementary mechanisms should be added." Insulin glargine addresses the fasting hyperglycemia that empagliflozin cannot adequately suppress when beta-cell function is severely reduced.

A practical starting point: add insulin glargine at 10 units nightly while continuing empagliflozin 10 mg. Titrate glargine by 2 units every 3 days to a fasting glucose target of 100 mg/dL. Empagliflozin's mild diuretic effect may require monitoring for volume depletion as insulin doses climb above 40 units.

When a True Switch Makes Sense

A true switch away from Jardiance is appropriate in three scenarios. First, the patient develops a urinary tract infection pattern that the prescribing clinician attributes to SGLT2-related glucosuria, confirmed after ruling out other causes. Second, eGFR falls below 20 mL/min/1.73 m², eliminating meaningful glycemic benefit. Third, the patient is scheduled for major surgery requiring perioperative NPO status, where SGLT2 inhibitors carry a risk of euglycemic diabetic ketoacidosis; hold empagliflozin 3 to 4 days before surgery per FDA guidance.

When Lantus Fails: Should You Switch to Jardiance or Add It?

Lantus failure in a patient who has never tried an SGLT2 inhibitor is an opportunity, not just a problem. The patient is likely accumulating cardiovascular risk, and empagliflozin's 38% relative reduction in cardiovascular death seen in EMPA-REG OUTCOME is available as add-on therapy. The 2023 ADA/EASD consensus report recommends SGLT2 inhibitors for patients with type 2 diabetes and heart failure or chronic kidney disease regardless of HbA1c or background therapy, including insulin.

Adding Empagliflozin to Insulin Glargine

Adding empagliflozin 10 mg to a stable insulin glargine regimen typically lowers HbA1c by an additional 0.5 to 0.7 percentage points and reduces body weight by 2 to 3 kg. The major safety issue is hypoglycemia: when glucose begins dropping from the combined renal excretion and insulin effect, insulin doses may need to be reduced by 10 to 20%. Monitor fasting glucose daily for the first 2 weeks after initiation.

When Lantus Itself Needs to Change

If basal insulin at doses above 0.5 units/kg/day fails to control fasting glucose despite confirmed adherence, the clinical problem is often significant postprandial glucose excursions that basal insulin alone cannot address. Adding a GLP-1 receptor agonist such as semaglutide (Ozempic) is frequently more effective than simply escalating basal insulin further. A meta-analysis published in Diabetes Care found that GLP-1 receptor agonist addition to basal insulin reduced HbA1c by 1.0 to 1.5% more than basal insulin titration alone.

Head-to-Head Comparison: Jardiance vs Lantus on Key Clinical Dimensions

| Dimension | Jardiance (empagliflozin) | Lantus (insulin glargine) | |---|---|---| | Mechanism | SGLT2 blockade, renal glucose excretion | Exogenous basal insulin supplementation | | Typical HbA1c reduction | 0.5 to 0.8% | 1.5 to 3.5% | | Weight | Down 2 to 3 kg | Up 1 to 4 kg | | Hypoglycemia risk (monotherapy) | Low | Moderate | | CV outcome data | EMPA-REG OUTCOME: 14% MACE reduction | ORIGIN: CV neutral | | Heart failure benefit | 35% reduction in HHF (EMPA-REG) | Not demonstrated | | CKD benefit | 39% reduction in nephropathy progression | Not demonstrated | | eGFR restriction | Reduced efficacy <45; avoid <20 | No eGFR restriction on dosing | | Route | Oral, once daily | Subcutaneous injection, once daily | | Cost (approximate US retail) | ~$550/month without insurance | ~$120 to 180/month (generic glargine available) |

Practical Prescribing: Combination Dosing and Monitoring

Starting the Combination

When both drugs are prescribed together, start one at a time to isolate tolerability. The usual sequence is to establish insulin glargine at a stable dose, then add empagliflozin 10 mg daily. Reduce glargine by 10 to 20% prophylactically at empagliflozin initiation if the patient's current fasting glucose is already at or below 120 mg/dL.

Monitoring Parameters

Check HbA1c at 3 months after any regimen change. Monitor eGFR and serum potassium at baseline and 6 months when combining SGLT2 inhibitors with insulin, because volume depletion from SGLT2 inhibition may concentrate electrolytes. The FDA label for empagliflozin specifically lists hypotension and volume depletion as risks requiring monitoring in patients on diuretic therapy or insulin.

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious risk when SGLT2 inhibitors are combined with insulin. Risk factors include very low carbohydrate diets, significant insulin dose reduction, surgery, or prolonged fasting. Patients should be counseled to check urine or blood ketones if they feel unwell, even with normal blood glucose readings.

Titration Algorithm for the Combination

A straightforward titration structure for clinical practice:

• Week 0: Establish insulin glargine 10 units nightly, add empagliflozin 10 mg daily
• Weeks 1 to 4: Increase glargine by 2 units every 3 days if fasting glucose exceeds 130 mg/dL
• Month 3: Check HbA1c; if still above target and fasting glucose is controlled, consider adding a GLP-1 agonist for postprandial coverage
• Ongoing: Review eGFR, body weight, and hypoglycemia frequency at every visit

Special Populations: Heart Failure, CKD, and Obesity

Heart Failure

Patients with type 2 diabetes and heart failure with reduced ejection fraction should remain on empagliflozin regardless of glycemic outcomes. EMPEROR-Reduced (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF, including those without diabetes. Insulin glargine has no comparable heart failure outcome data.

Chronic Kidney Disease

Empagliflozin is now recommended in CKD with eGFR as low as 20 mL/min/1.73 m² for kidney protection, even though glycemic benefit is minimal at that level. The EMPA-KIDNEY trial (N=6,609) confirmed that empagliflozin reduced kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) in patients with CKD. Insulin glargine dose requires no adjustment for eGFR but hypoglycemia risk increases as renal insulin clearance falls.

Obesity With Type 2 Diabetes

Jardiance produces modest weight loss (2 to 3 kg) insufficient for patients who need substantial weight reduction. Lantus causes weight gain. For patients with BMI above 35 kg/m², adding semaglutide 2.4 mg weekly (Wegovy) or tirzepatide (Mounjaro) may achieve glycemic control that allows insulin dose reduction or discontinuation. SURMOUNT-3 (N=579) showed that tirzepatide reduced body weight by 18.4% over 72 weeks in patients with obesity and type 2 diabetes who had previously been on basal insulin.

Frequently Asked Questions